Vaxil Bio Ltd experienced a slight decline in its stock price this week despite some recent fundraising activities.
Vaxil Bio Ltd (VXL.V) has had a mixed performance in the stock market. While there was a notable increase over the past week, today’s trading saw a decline. The company has been actively securing funds through private placements, which could influence investor sentiment moving forward.
Advertisement
Vaxil Bio Ltd
VXL.V
VXL.V
Vaxil Bio Ltd
WealthAwesomeMarket cap
$677,283
P/E
1.1x
52W high
$0.29
52W low
$0.13
1W change
+6.25%
Beta
-0.87
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VXL's historical volatility
30-Day Vol
74.6%
Annualized
90-Day Vol
108.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.14
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.16 | C$0.12 – C$0.21 |
| 60 trading days | C$0.15 | C$0.10 – C$0.22 |
| 90 trading days | C$0.14 | C$0.09 – C$0.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Vaxil Bio's recent fundraising efforts might provide the capital needed to pursue its business goals, but the stock remains highly volatile, as shown by its performance metrics.
Vaxil Bio's stock has increased by 6.25% over the past week.
Despite these recent gains, the stock is down 2.86% today, reflecting the volatility often associated with small-cap biotech firms.
Bull case
The recent private placement could strengthen Vaxil's financial position and support its operational initiatives, potentially leading to future growth.
Bear case
Even with the recent fundraising, the company's stock price remains low and may struggle to gain investor confidence, especially after the termination of a significant reverse takeover deal.
Price Action Overview
Advertisement
Vaxil Bio Ltd's stock closed at C$0.17, reflecting a 2.86% decline in today’s trading. However, the stock has gained 6.25% over the past week, demonstrating the volatility typical of small-cap biotech firms.
Recent Company News
This week, Vaxil Bio completed a private placement, raising C$140,000 by issuing 1,244,441 units at C$0.1125 each. Each unit consists of one common share and one warrant, exercisable at C$0.15 until December 2, 2030. The company also announced updates to its board of directors. Additionally, there was a revision of terms for a larger private placement initially aimed at raising C$350,000, reflecting ongoing efforts to secure funding for operational needs.
Technical Picture
Currently, Vaxil Bio's stock is trading at its 50-day moving average of C$0.17, with a slight 1.6% premium over this average. The 200-day moving average also stands at C$0.17, indicating stability in the longer-term trend. Over the past 52 weeks, the stock has ranged from C$0.13 to C$0.29, with its current price at 25% of this range. The stock has a beta of -0.87, suggesting it may be less volatile than the broader market. However, trading volume today was 2,000 shares, significantly below the 20-day average volume of 4,254 shares, pointing to lower investor activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
